ArticleInternational urology and nephrology2011
Rapamycin-induced posterior reversible encephalopathy in a kidney transplantation patient.
Article in International urology and nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 17 citations in OpenAlex.
- Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact.Bone marrow transplantation · 2018Article
- Neurological complications of new chemotherapy agents.Neuro-oncology · 2018Article
- Posterior reversible encephalopathy syndrome in children with kidney disease.International urology and nephrology · 2017Review
- Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review.Molecular neurobiology · 2016Review
- American society of Nephrology Quiz and Questionnaire 2014: transplantation.Clinical journal of the American Society of Nephrology : CJASN · 2015Article
- Neurotoxicity of biologically targeted agents in pediatric cancer trials.Pediatric neurology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPosterior reversible encephalopathy syndrome (PRES) is characterized by abnormalities in cerebral white matter and neurologic symptoms. It can be caused by immunosuppressive drugs or autoimmune diseases. We describe a case of PRES in a kidney transplantation patient treated with rapamycin. CASE: A 24-year-old woman, who received kidney transplantation 8 years ago, presented hypertension (220/120 mmHg), blindness, paralysis of left extremities, vomiting, convulsions and unconsciousness after rapamycin treatment. Magnetic resonance imaging (MRI) showed brain lesions suggestive of PRES. Rapamycin was withdrawn, and repeated MRI indicated progressive resolution within 2 months.
conclusionAlthough neurotoxicity of rapamycin is relatively low, it can induce PRES in kidney transplantation patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.